MVP Share Price Performance
AU$0
-0.42 (-100.00%)
Price AU$0
Fair ValueAU$2.27
Share Pricen/a
Medical Developments International Limited (ASX:MVP) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
Dec 01
Medical Developments International Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 17 Fair Values set on narratives written by author
MVP Community Narratives
AN
Fair Value AU$2.27 76.4% undervalued intrinsic discount
European Approvals And Distribution Partnerships Will Expand Global Reach
0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
AN
Fair Value AU$0.8 33.1% undervalued intrinsic discount
European Delays And Tariff Pressures Will Weigh As Potential Emerges
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value AU$3.73 85.7% undervalued intrinsic discount
Aging Demographics Will Power Global Portable Pain Relief
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
European Approvals And Distribution Partnerships Will Expand Global Reach
Key Takeaways Regulatory approvals and strategic partnerships are expanding market access for Penthrox, driving revenue growth and improved operational leverage in key markets. Increased demand for non-opioid pain relief, manufacturing efficiencies, and cost discipline are strengthening competitive positioning and supporting margin expansion.Read more
0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
AN
AU$2.27
76.4% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue
11.82% p.a.
Profit Margin
7.88%
Future PE
71.22x
Price in 2028
AU$2.72
European Delays And Tariff Pressures Will Weigh As Potential Emerges
Key Takeaways Heavy reliance on a single product and difficult regulatory environments create significant risks for revenue growth and long-term earnings stability. Intensifying competitive, cost, and operational pressures may delay profitability gains, especially without faster product adoption and revenue diversification.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AU$0.8
33.1% undervalued intrinsic discount
AnalystLowTarget Fair Value
Revenue
12.1% p.a.
Profit Margin
2.34%
Future PE
84.06x
Price in 2028
AU$0.96
Aging Demographics Will Power Global Portable Pain Relief
Key Takeaways Rapid adoption of portable analgesia and broader regulatory support could drive significantly faster revenue and earnings growth than currently anticipated. Innovation pipeline in pre-hospital and emergency care will unlock new recurring revenue streams, diversify earnings, and structurally expand margins.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AU$3.73
85.7% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue
12.49% p.a.
Profit Margin
14.23%
Future PE
63.74x
Price in 2028
AU$4.48
Trending Discussion
Recently Updated Narratives
AN
European Delays And Tariff Pressures Will Weigh As Potential Emerges
Fair Value: AU$0.8 33.1% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Demographics Will Power Global Portable Pain Relief
Fair Value: AU$3.73 85.7% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
European Approvals And Distribution Partnerships Will Expand Global Reach
Fair Value: AU$2.27 76.4% undervalued intrinsic discount
12 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Medical Developments International Limited Key Details
About MVP
- Founded
- 1972
- Employees
- n/a
- CEO
- WebsiteView website
Medical Developments International Limited manufactures and distributes emergency medical solutions in Australia, Asia, Europe, the United States, and internationally. The company operates through Pain Management and Respiratory segments. It offers Penthrox, a trauma and emergency pain relief product for use in hospitals, emergency departments, ambulance services, sport medicines, and for analgesia during short procedures. The company also distributes asthma and chronic obstructive pulmonary disease products, such space chambers, peak flow meters, portable nebulisers, and silicon face mask. Medical Developments International Limited was founded in 1972 and is headquartered in Scoresby, Australia.
